Sachs Associates’ Post

Adoram Therapeutics, a University of Geneva spin-off, is developing next-generation (allosteric) small molecule drugs, which are safer and more effective than conventional (orthosteric) small molecules. We have developed an allosteric screening platform to efficiently identify positive or negative modulators of GPCR drug targets. We are securing investments to progress two preclinical stage assets towards human trials, and to expand our pipeline. Meet Adoram Therapeutics @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

2024 Life Science #IPOs! Key drivers include: Later stage assets and #clinical #trial results. Multiple early stage assets with #platform technology TA Focus: #Oncology / #cancer, #Neuro/ #CNS; #Inflammation/ #Immunology TM focus #smallmolecules, #biologics, #genetherapy, and #celltherapy. The median #IPO is $110M with a high of $380M. #funding #publicofferings #biotech #biopharma Kyverna Therapeutics; CG Oncology; Contineum Therapeutics; Boundless Bio; Chromocell Corporation; Metagenomi; Telomir Pharmaceuticals, Inc.; Alto Neuroscience; Fractyl Health; Autonomix Medical; ArriVent Biopharma #ai #datascience #machinelearning #ML #VC #biopharma #biotech #CFO #ipos

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy.  We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

At Obatala, we are working to further the development of new treatments for #metabolicdiseases including #diabetes. The different rates of disease in different populations requires more accurate modeling of these populations during preclinical drug research, something that we enable with the variety of the donor population of our adipose-derived stem cells. Reach out if you want to learn more about how we use these cells in our ObaCell® Fat-on-a-Chip and ObaCell® Obesity-on-a-Chip models! #microphysiologicalsystem #organonachip

Delta4ai is an AI Drug Discovery Biotech Company with a focus on Indication Expansion. By utilizing Hyper-C, a proprietary artificial intelligence powered platform, Delta4's team detects relationships between drugs with a known safety profile and diseases with unprecedented speed. Meet Delta4 GmbH @ #Sachs_BEF More Info @ https://lnkd.in/eQkiWD2h #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Biotech startup Mirador Therapeutics has launched with a whopping $400 million in funding to revolutionize precision medicine for “immune-mediated inflammatory and fibrotic diseases.” While the company has not yet revealed which indications it is targeting, there are many chronic conditions that could potentially fall under such a scope, including rheumatoid arthritis, connective tissue disorders, and even neurological diseases such as multiple sclerosis. Mirador aims to address the treatment gap in immune-mediated diseases by tailoring treatments to individual genetic profiles, a strategy that has dramatically changed approaches in oncology. At the heart of the company’s strategy is its “precision development engine,” Mirador360, which harnesses recent advancements in human genetics and data science. The platform is designed to sift through vast amounts of patient data to uncover genetic associations to immune-mediated diseases, identify therapeutic targets, and explore potential combination therapies. Key to Mirador’s approach is its emphasis on genetic profiling. By pinpointing specific genetic targets, the company hopes to not only develop more effective treatments but also advance diagnostics and refine patient stratification for clinical trials.

Akribion Genomics develops a revolutionary, genetically-programmable and new therapy class for oncology, using novel nucleases, causing programmable cell depletion via RNA biomarker recognition. The nuclease can target a wide variety of cancer indications defined by genetic make up of patients and can also be applied beyond oncology. The nucleases are protected by a s trong IP position with FTO and the key patent granted in September 2023. The technology had initially been developed within and the company is a spin out of BRAIN Biotech, a stock listed industrial Biotech player that focuses on industrial applications. Meet Akribion Genomics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

Cancer Biomarkers Market worth USD 42.0 Billion | Growing at a CAGR of 11.3% Download PDF Brochure: https://lnkd.in/dgT6_KtE The size of global #cancer #biomarkers market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US). 𝐎𝐭𝐡𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐥𝐨𝐛𝐚𝐥𝐥𝐲: Eureka Genomics New Path Molecular Research      QCDx Epify BV KeViRx, Inc. BioTether Sciences Inc.  BreakSight, Inc.      Exosome Sciences Inc InsideDNA Exosome Analytics  AnyGenes® EVIIVE Omnigene Medical Technologies Ltd Microgentas  Pure MHC, LLC Bioprognos Pace Diagnostics, Inc. Axaitech OncoSeer Diagnostics, Inc. Biosens Labs VarCT Diagnostics StoreMyTumor Avatrial PreCyte Inc NeuScience DKP Genomics, LLC BioMavericks Ymir Genomics OncoAssure Ltd Acuimmune Infiniplex Kurglab MD Healthcare Inc.   Cellgebra EviStat Angarus Therapeutics Fluidia Biosettia Inc. GenoDeep Gliotrack

The Future of Diagnostics and the Impact on Deals Listen to PharmaVentures' latest podcast: https://lnkd.in/d6BB-6wE Listen as Andreas Katsiamides, Ph.D. talks with Adrian Dawkes about the future of diagnostics and the impact on deals. They discuss: - Technological advances in diagnostics, such as artificial intelligence (AI), next-generation sequencing (NGS) and polymerase chain reaction (PCR) testing - Its application to specific medical models and therapy areas – including personalised medicine, oncology, and Alzheimer’s - Key players in the area, and their commercial models - The importance of diagnostics working hand-in-hand with therapeutics - Licensing and M&A transactions, and the potential deal values in the future #Diagnostics  #Cancer #Oncology #AlzheimersDisease #PrecisionMedicine #PersonalisedMedicine #CompanionDiagnostics #Licensing #Partnering #MergersandAcquisitions #AI #Valuations #MedTech #Podcast #JPMWeek #JPM24 #BiotechShowcase #TheDealExperts

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. The company is working with a range of pharmaceutical license partners to develop a portfolio of CAR-IMAN cell therapies to deliver complete remission across all solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer.  LIfT IMANs have preclinical validation of all of the characteristics required to overcome the challenges to achieving sustained remission in solid tumours. Meet LIfT BioSciences @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW